TARA

MKT CAP:$202M

Protara Therapeutics, Inc.

Market Cap

$202M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.26-$0.12 (-2.23%)

Apr 23, 2026

Company Details

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigatio...

CEO

Jesse Shefferman

IPO Date

Oct 22, 2014

Website

www.protaratx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$57M

EPS (Diluted)

-$1.33

Free Cash Flow

-$56M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 10, 2026

$0EPS -$1.34

Q4 2025

Mar 10, 2026

$0EPS -$0.38

Q3 2025

Nov 10, 2025

$0EPS -$0.31

Q2 2025

Aug 11, 2025

$0EPS -$0.35

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$11M
Q2 22	$0	$0	-$9M
Q3 22	$0	$0	-$8M
Q4 22	$0	$0	-$40M
Q1 23	$0	$0	-$10M
Q2 23	$0	$0	-$12M
Q3 23	$0	$0	-$11M
Q4 23	$0	$0	-$11M
Q1 24	$0	-$83.0K	-$12M
Q2 24	$0	$0	-$11M
Q3 24	$0	$0	-$12M
Q4 24	$0	$0	-$14M
Q1 25	$0	$0	-$14M
Q2 25	$0	$0	-$17M
Q3 25	$0	-$88.0K	-$15M
Q4 25	$0	-$93.0K	-$19M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$11M	-$11M
Q2 22	-$5M	-$5M
Q3 22	-$5M	-$5M
Q4 22	-$5M	-$5M
Q1 23	-$13M	-$13M
Q2 23	-$9M	-$9M
Q3 23	-$7M	-$7M
Q4 23	-$9M	-$9M
Q1 24	-$10M	-$10M
Q2 24	-$8M	-$8M
Q3 24	-$8M	-$8M
Q4 24	-$9M	-$9M
Q1 25	-$15M	-$15M
Q2 25	-$12M	-$12M
Q3 25	-$12M	-$12M
Q4 25	-$17M	-$17M

Capital Expenditures

Quarter	CapEx
Q1 22	$11.0K
Q2 22	$20.0K
Q3 22	$83.0K
Q4 22	$6.0K
Q1 23	$6.0K
Q2 23	$2.0K
Q3 23	$37.0K
Q4 23	$0
Q1 24	$0
Q2 24	$55.0K
Q3 24	$8.0K
Q4 24	$0
Q1 25	$44.0K
Q2 25	$22.0K
Q3 25	$4.0K
Q4 25	$24.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-19.9%
Q2 22	—	-31.9%
Q3 22	—	-26.4%
Q4 22	—	+284.1%
Q1 23	—	-10.5%
Q2 23	—	+39.5%
Q3 23	—	+34.2%
Q4 23	—	-72.1%
Q1 24	—	+21.8%
Q2 24	—	-12.2%
Q3 24	—	+15.2%
Q4 24	—	+29.6%
Q1 25	—	+19.2%
Q2 25	—	+55.6%
Q3 25	—	+19.7%
Q4 25	—	+33.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$1M	—
Q4 22	$1M	—
Q1 23	$2M	—
Q2 23	$0	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$1M	—
Q2 24	$1M	—
Q3 24	$931.0K	—
Q4 24	$904.0K	—
Q1 25	$833.0K	—
Q2 25	$903.0K	—
Q3 25	$1M	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$5M	$6M	—
Q2 22	$3M	$6M	—
Q3 22	$3M	$5M	—
Q4 22	$5M	$5M	—
Q1 23	$5M	$5M	—
Q2 23	$7M	$5M	—
Q3 23	$6M	$4M	—
Q4 23	$6M	$5M	—
Q1 24	$8M	$4M	—
Q2 24	$6M	$4M	—
Q3 24	$8M	$4M	—
Q4 24	$9M	$5M	—
Q1 25	$9M	$5M	—
Q2 25	$11M	$6M	—
Q3 25	$10M	—	$5M
Q4 25	$13M	$6M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$25M	$62M	$88M
Q2 22	$34M	$65M	$98M
Q3 22	$47M	$49M	$96M
Q4 22	$24M	$60M	$84M
Q1 23	$21M	$66M	$87M
Q2 23	$34M	$46M	$80M
Q3 23	$34M	$40M	$74M
Q4 23	$40M	$26M	$66M
Q1 24	$52M	$3M	$55M
Q2 24	$90M	$0	$90M
Q3 24	$52M	$30M	$81M
Q4 24	$163M	$7M	$170M
Q1 25	$91M	$33M	$124M
Q2 25	$31M	$91M	$122M
Q3 25	$13M	$120M	$133M
Q4 25	$50M	$106M	$156M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	11M	+0.1%	+0.2%
Q2 22	11M	+0.0%	+0.2%
Q3 22	11M	+0.1%	+0.3%
Q4 22	11M	+0.0%	+0.3%
Q1 23	11M	+0.3%	+0.5%
Q2 23	11M	+0.0%	+0.5%
Q3 23	11M	+0.4%	+0.7%
Q4 23	11M	+0.1%	+0.9%
Q1 24	11M	+0.5%	+1.0%
Q2 24	21M	+85.9%	+87.8%
Q3 24	22M	+5.2%	+96.8%
Q4 24	26M	+18.4%	+132.6%
Q1 25	41M	+54.0%	+256.4%
Q2 25	42M	+3.8%	+99.1%
Q3 25	42M	+0.0%	+89.3%
Q4 25	46M	+8.9%	+74.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	32
Q2 22	$0	32
Q3 22	$0	32
Q4 22	$0	25
Q1 23	$0	25
Q2 23	$0	25
Q3 23	$0	25
Q4 23	$0	26
Q1 24	$0	26
Q2 24	$0	26
Q3 24	$0	26
Q4 24	$0	28
Q1 25	$0	28
Q2 25	$0	28
Q3 25	$0	28
Q4 25	$0	90K

Revenue / Employee